Pulmonary arterial hypertension during systemic lupus
G. Cinquetti(Hôpital d'instruction des Armées Desgenettes), Jean Sibilia(Immunologie, Immunopathologie et Chimie Thérapeutique), Emmanuel Chatelus(Laboratoire National de Référence), Rose‐Marie Javier(Laboratoire National de Référence), Cécile Ronde-Oustau(Hôpital d'Hautepierre), Jacques‐Eric Gottenberg(Hôpitaux Universitaires de Strasbourg), Christelle Sordet
Cited by 1
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432